Document 0716
 DOCN  M94A0716
 TI    HIV vaccines.
 DT    9412
 AU    Corey L; McElrath J; Kent S; Greenberg P; University of Washington,
       Seattle.
 SO    Annu Conf Australas Soc HIV Med. 1993 Oct 28-30;5:22 (abstract no.
       FPI-1). Unique Identifier : AIDSLINE ASHM5/94348939
 AB    To date the NIAID sponsored AIDS Vaccine Evaluation Group (AVEU) has
       enrolled over 1000 patients into Phase I/II clinical trials of candidate
       HIV vaccines. 8 different envelope products have been evaluated
       including two gp160 preparations, two subunit gp120 products, one yeast
       derived gp120, one vaccinia gp160, 1 canarypox gp160, and one envelope
       peptide based vaccine. All the vaccines have been immunogenic and
       adverse effects have been limited to transient local reactions. Direct
       comparison of immune responses is not possible in all cases due to
       varying stages of development, the varying doses of vaccine and the
       different adjuvants employed in the products. Overall, the two gp120
       products have proven to elicit the highest neutralising antibody titers
       among health seronegative vaccines. Over 90% of recipients receiving a
       0, 1, 6 month regimen have detectable neutralising responses; the mean
       neutralising titer average about 1:100, about 5-fold lower than that
       seen with persons with naturally acquired HIV infection. T cell
       lymphoproliferative responses are elicited by all of these vaccines
       However, none of the subunit vaccines alone have elicited detectable
       CD8+ cytolytic activity to HIV envelope (0 of 40 tested). However, 2 of
       8 vaccinia naive individuals who have received a regimen consisting of
       priming with a vaccinia recombinant and boosting with a gp160 subunit
       protein have had detectable persistent CD8+ CTLs. A detailed description
       of the above Phase I and II trials will be given.
 DE    Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*PREVENTION &  CONTROL
       AIDS Vaccines/*ADMINISTRATION & DOSAGE/IMMUNOLOGY  Human  HIV
       Antibodies/BIOSYNTHESIS  HIV Envelope Protein gp120/ADMINISTRATION &
       DOSAGE/IMMUNOLOGY  HIV Infections/IMMUNOLOGY/*PREVENTION & CONTROL
       Immunization Schedule  Vaccines, Synthetic/ADMINISTRATION &
       DOSAGE/IMMUNOLOGY  CLINICAL TRIAL  CLINICAL TRIAL, PHASE I  CLINICAL
       TRIAL, PHASE II  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).